Zydus Lifesciences Ltd (ZYDU)

NSE
Currency in INR
1,008.20
+31.20(+3.19%)
Closed
ZYDU Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Unusual trading volume
Fair Value
Day's Range
976.001,026.55
52 wk Range
768.801,324.30
Key Statistics
Edit
Bid/Ask
1,007.75 / 1,008.20
Prev. Close
977
Open
984
Day's Range
976-1,026.55
52 wk Range
768.8-1,324.3
Volume
5.78M
Average Vol. (3m)
1.21M
1-Year Change
22.52%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZYDU Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
1,078.00
Upside
+6.92%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry
Show more

Zydus Lifesciences Ltd Company Profile

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Employees
26921
Market
India

Compare ZYDU to Peers and Sector

Metrics to compare
ZYDU
Peers
Sector
Relationship
P/E Ratio
22.4x28.8x−0.6x
PEG Ratio
0.420.670.00
Price / Book
4.6x5.3x2.6x
Price / LTM Sales
4.6x4.5x3.1x
Upside (Analyst Target)
6.9%17.5%51.7%
Fair Value Upside
Unlock−7.0%7.5%Unlock

Analyst Ratings

15 Buy
10 Hold
6 Sell
Ratings:
31 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1,078.00
(+6.92% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 45.03
Dividend Yield
0.31%
Industry Median 0.70%
Annualized Payout
3
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 05, 2025
EPS / Forecast
10.10 / 9.26
Revenue / Forecast
52.69B / 54.40B
EPS Revisions
Last 90 days

People Also Watch

33.84
SMCI
+7.46%
29.01
KHC
+1.40%
1,198.40
MACE
-5.52%
231.36
AVGO
-0.28%
502.84
MCO
+1.41%

FAQ

What Is the Zydus Lifesciences (ZYDU) Stock Price Today?

The Zydus Lifesciences stock price today is 1,008.20

What Stock Exchange Does Zydus Lifesciences Trade On?

Zydus Lifesciences is listed and trades on the NSE stock exchange.

What Is the Stock Symbol for Zydus Lifesciences?

The stock symbol for Zydus Lifesciences is "ZYDU."

Does Zydus Lifesciences Pay Dividends? What’s The Current Dividend Yield?

The Zydus Lifesciences dividend yield is 0.30%.

What Is the Zydus Lifesciences Market Cap?

As of today, Zydus Lifesciences market cap is 1.01T.

What is Zydus Lifesciences Earnings Per Share?

The Zydus Lifesciences EPS is 45.03.

What Is the Next Zydus Lifesciences Earnings Date?

Zydus Lifesciences will release its next earnings report on May 30, 2025.

From a Technical Analysis Perspective, Is ZYDU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.